TRON is delighted to announce an article published in Oncoimmunology. TRON co-author Nadja Salomon shares this Author’s Comment. HPV16 infections are associated with a variety of cancers and there is compelling evidence that the transforming activity of HPV16 critically depends on the expression of the viral oncoproteins E6 and E7. Therapeutic cancer vaccines capable of
At the Healthcare Hackathon at the University Medical Center Mainz, experts from the field of healthcare met with startups, programmers, and industry partners. In interdisciplinary mixed teams, technology-based solutions were developed for practical challenges in hospitals and care. For TRON, Jonas Ibn-Salem participated in the hackathon and worked with experts from IBM, Garmin, BioNTech and
At the annual meeting of the Association for Cancer Immunotherapy (CIMT) in 2019, six scientists received the CIMT Poster Award. Thomas Rösler, a scientist from TRON, won the prize in the category ‘Therapeutic Vaccination’ for his work ‘Modelling immunogenicity with omics data integration’ (Abstract 37). He presented his algorithm TOPAZ, which defines candidates for cancer
The Association for Cancer Immunotherapy CIMT’s Annual Meeting brings the world’s top cancer biology and immunotherapy researchers together in the heart of Europe. The 2019 Annual Meeting will take place May 21-23 at the Rheingoldhalle Congress Center in Mainz.
Hannover, May 8, 2019 – The Center for Individualised Infection Medicine CiiM lecture series is held at Hannover Medical School. Ugur Sahin will be speaking about Individualized Cancer Immunotherapy on Wednesday, May 8th at 17:00, in Building J01, Lecture Hall N. CiiM is a joint institution of the Helmholtz Center for Infection Research (HZI) and
Professor Ugur Sahin erhält den Deutschen Krebspreis 2019 Mainz, 28. Februar 2019 – Univ.-Prof. Dr. Ugur Sahin hat den Deutschen Krebspreis 2019 erhalten – eine der angesehensten Auszeichnungen in der Krebsmedizin in Deutschland. Prof. Sahin erhält den Preis in der Kategorie Transferforschung für seine wegweisenden Arbeiten zu individualisierten Krebsimmuntherapien, insbesondere für die Entwicklung und klinische
Official foundation ceremony of HI-TRON Mainz Mainz, February 14, 2019 – The new Helmholtz Institute for Translational Oncology (HI-TRON Mainz) is to become one of the world’s leading centers for personalized cancer immunotherapy. This is the ambitious goal of the cooperation partners German Cancer Research Center (DKFZ) and the Research Institute Translational Oncology (TRON gGmbH)
Mainz, January 31, 2019 – TRON celebrates young talent TRON is sponsoring two scholarships in the Deutschlandstipendium 2018/2019 of the Johannes Gutenberg University Mainz, thereby supporting two young medical students as part of this Federal Ministry of Education and Research program. On January 31st, the festive dinner for Deutschlandstipendium sponsors and scholarship holders took place
Mainz, February 5, 2019 – The 1st German Cancer Research Congress (GCRC) is taking place in Heidelberg 4-5 February, showcasing the best cancer research in Germany. Ugur Sahin will speak in the session on Tumor Immunology and Immunotherapy on Tuesday, February 5th. For more information on this event, please see the official DKFZ website.
Mainz, February 5, 2019 – TRON is thrilled to announce a review published in Annual Review of Medicine authored by Ugur Sahin. In this overview article targeting the medical community, Prof. Sahin defines the cancer mutanome and why this is a valuable source of potential vaccines targets in oncology. The review goes on to describe
Mainz, January 21, 2019 – The Keystone Symposium on Cancer Vaccines is occurring 20-24 January, 2019, at the Fairmont Hotel in Vancouver, Canada. Ugur Sahin will speak in the session on Novel Cancer Vaccine Platforms on Wednesday, January 23rd. The title of his lecture is “RNA-based Vaccines”. For more information on this event,
Mainz, December, 2018 – TRON is proud to have taken part in the research that lead to this publication in OncoImmunology. This publication – in collaboration with scientists from BioNTech, DKFZ, JPT, and the University Medicine Mainz – points to hurdles on our way to highly personalized cancer immunotherapy. The research group investigated neoepitope-specific CD8+